Executive record

Fred Hassan

Director at Cocrystal Pharma, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:fred-hassanVersion: public-0As of: 2026-09-28

Not yet claimed10 published Claims4 sources
  • Director

Key Claims

Biography

Mr. Hassan previously served as Chairman and Chief Executive Officer of Schering-Plough from 2003 to 2009 and Pharmacia Corporation from 2001 to 2003. He has extensive leadership experience in global pharmaceutical companies and serves on multiple boards.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. 2026 to end not publishedExecutive title: Director · Organization not publishedCOCP 10-K executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. COCP 10-K executive officers

    sec filing · Source published: Mar 31, 2026 · Retrieved: May 16, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Cocrystal Pharma, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Director · Claim reviewed: May 16, 2026
    • Other Company Role: Fred Hassan is also linked to Warburg Pincus LLC as Advisor. · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  2. COCP DEF 14A director slate

    sec filing · Source published: May 5, 2025 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  3. Open source

    sec proxy · Source published: May 5, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at Cocrystal Pharma, Inc. · Claim reviewed: May 16, 2026

  4. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Cocrystal Pharma, Inc. · Claim reviewed: May 16, 2026